Replies to post #317068 on Innovation Pharmaceuticals Inc (IPIX)

[tfris]

As I said, good luck. Doubt he ever gets anything to market.

[LilyGDog]

Another awesome post KarinCA!

Go Leo & IPIX!

_______________________________________________________________________

Brilacidin has passed safety benchmarks in multiple clinical trials and, is currently being tested as a covid therapeutic in two US RBL’s.

Brilacidin for ABSSSI is ph3 ready. Ph2 was dosed via IV in hundreds of patients.

Brilacidin for OM is ph3 ready. Ph2 was dosed via swish and spit.

Brilacidin for UP ph 2 POC trial was dosed with water enema. Results good enough that Alfasigma licensed Brilacidin for UP dosing with foam, enema, or gel.

Brilacidin for UC ph 1 was dosed with Oralogic tablet.

*****

http://www.ipharminc.com/press-release/2020/5/26/innovation-pharmaceuticals-receives-data-from-public-health-research-institute-showing-brilacidin-inhibits-sars-cov-2-covid-19-in-a-human-cell-line
Quote:
· Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2
· Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells

*****

https://www.globenewswire.com/news-release/2020/06/11/2046799/0/en/Innovation-Pharmaceuticals-Collaborating-with-Regional-Biocontainment-Lab-on-Grant-Application-to-Research-Brilacidin-as-a-Pan-Coronavirus-Therapeutic.html
Quote:
a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.

This is likely to have been submitted on Friday the 12th and, that is the date I’ll be using for my purposes.
Quote:
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing.

The question remains as to whether or not this grant is approved. This will be helped by the fact testing is being conducted by US RBL's and not internal company testing. Imagine the benefit if Brilacidin shows to be active in other virus's. Especially, the common cold.

Probability is finally on our side as shareholders due to the seriousness and intensity of the global concern surrounding covid. The science is also with us.

In vitro results have been very good in human lung and kidney cells. The safety has been proven in 3 FDA studies with about 500 patients. Immunomodulation will likely reduce pulmonary and inflammatory complications. The virucidal MOA results in faster viral clearance. And, the broad spectrumm antibiotic will likely reduce high rate of secondary infection. It's the only treatment with 3 MOA which should reduce drug resistance. The good pharmockinetics with long half life will increase antiviral effect and reduce may reduce frequency of dosing.

And, I don’t believe Leo would make false covid claims with the SEC watching this arena closely.

SEC Charges Companies and CEO for Misleading COVID-19 Claims
https://www.sec.gov/news/press-release/2020-111

[thefamilyman]

Well put!

You said,

Brilacidin has passed safety benchmarks in multiple clinical trials and, is currently being tested as a covid therapeutic in two US RBL’s.

Brilacidin for ABSSSI is ph3 ready. Ph2 was dosed via IV in hundreds of patients.

Brilacidin for OM is ph3 ready. Ph2 was dosed via swish and spit.

Brilacidin for UP ph 2 POC trial was dosed with water enema. Results good enough that Alfasigma licensed Brilacidin for UP dosing with foam, enema, or gel.

Brilacidin for UC ph 1 was dosed with Oralogic tablet.

*****

www.ipharminc.com/press-release/2020/5/26/innovation-pharmaceuticals-receives-data-from-public-health-research-institute-showing-brilacidin-inhibits-sars-cov-2-covid-19-in-a-human-cell-line
Quote:
· Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2
· Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells

*****

https://www.globenewswire.com/news-release/2020/06/11/2046799/0/en/Innovation-Pharmaceuticals-Collaborating-with-Regional-Biocontainment-Lab-on-Grant-Application-to-Research-Brilacidin-as-a-Pan-Coronavirus-Therapeutic.html
Quote:
a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.

This is likely to have been submitted on Friday the 12th and, that is the date I’ll be using for my purposes.
Quote:
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing.

The question remains as to whether or not this grant is approved. This will be helped by the fact testing is being conducted by US RBL's and not internal company testing. Imagine the benefit if Brilacidin shows to be active in other virus's. Especially, the common cold.

Probability is finally on our side as shareholders due to the seriousness and intensity of the global concern surrounding covid. The science is also with us.

In vitro results have been very good in human lung and kidney cells. The safety has been proven in 3 FDA studies with about 500 patients. Immunomodulation will likely reduce pulmonary and inflammatory complications. The virucidal MOA results in faster viral clearance. And, the broad spectrumm antibiotic will likely reduce high rate of secondary infection. It's the only treatment with 3 MOA which should reduce drug resistance. The good pharmockinetics with long half life will increase antiviral effect and reduce may reduce frequency of dosing.